Alterations in the PI3K/AKT/MTOR pathway have been identified as driver mutations in primary NSCLC lung cancer but also to be known as the biomarkers of resistance to EGFR-tyrosine kinase inhibitors [44]. This evidence concerns the gene EGFR and lung carcinoma.